Interplay between nuclear factor erythroid 2-related factor 2 and inflammatory mediators in COVID-19-related liver injury

Dan-Dan Zhu, Xue-Mei Tan, Li-Qing Lu, Si-Jia Yu, Ru-Li Jian, Xin-Fang Liang, Yi-Xuan Liao, Wei Fan, Lucíia Barbier-Torres, Austin Yang, He-Ping Yang, Ting Liu

Author contributions: Zhu DD, Tan XM, and Lu LQ contributed equally in reviewing the literature and drafting the manuscript; Yu SJ, Jian RL, Liang XF, Liao YX, and Fan W assisted in the literature review and drafting the manuscript; Barbier-Torres L provided critical reading of the manuscript; Yang A provided English editing and revisions; Liu T and Yang HP provided critical editing and revisions of the manuscript; All authors have read and approved the final manuscript.

Supported by National Natural Science Foundation of China, No. 82070632.

Conflict-of-interest statement: None of the authors have any conflict of interest.

Open-Access: This article is an Open-Access article subjected to the Creative Commons Attribution License.
INTRODUCTION

Coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared to be a global pandemic by the World Health Organization in 2020. COVID-19 is caused by infection with SARS-CoV-2, which has a single-stranded RNA approximately 26-32 kb in length and belongs to the same coronavirus family as Middle East respiratory syndrome coronavirus and SARS-CoV-1[1,2].

Viral toxicity, body immunity, and the induced inflammatory response all affect the occurrence and progression of COVID-19[3]. The commonly accepted method of transmission is that SARS-CoV-2 binds to the receptor angiotensin-converting enzyme 2 (ACE2) on cells through its spike (S) glycoprotein, which has two domains, S1 and S2, with the former binding the peptidase domain of ACE2, called the receptor-binding domain, and the latter catalyzing membrane fusion to release genetic material into the cell[4,5]. After entry, SARS-CoV-2 interferes with the host’s immune defenses, evades host immune surveillance, and rapidly replicates. The replication of the virus activates monocytes, macrophages and granulocytes, accompanied by the release of many reactive oxygen species (ROS) and inflammatory cytokine storms, which eventually lead to tissue inflammatory cell infiltration, necrosis, and fibrosis[3,6].

The pathological mechanism of SARS-CoV-2 infection is very complex and unclear. It is now widely believed to be associated with the host’s immune response, the inflammatory response, and oxidative stress[3]. It manifests with moderate to severe respiratory symptoms and is usually accompanied by multiple organ dysfunction syndrome (MODS)[7]. Based on the pathogenesis of COVID-19, it has been hypothesized that SARS-CoV-2 might directly bind to the receptor ACE2, which is widely distributed among body tissues, such as liver tissue, and is considered a target for SARS-CoV-2 entry, which causes inflammation, oxidative stress, and proapoptotic reactions, ultimately leading to liver injury[5]. SARS-CoV-2 can directly cause bile duct epithelial cell dysfunction and affect hepatocyte regeneration and the immune response[8]. Liver dysfunction is a common complication and mainly manifests as elevated transaminase and bilirubin levels[9-12]. According to statistics, 5.1%-69.8% of patients with COVID-19 suffer from liver dysfunction, occurring more commonly in patients with other severe symptoms[13,14], and 2.1%-4.1% of patients with COVID-19 undergo pre-existing liver disease[14]. Interestingly, liver dysfunction appears earlier in COVID-19-related MODS, most likely because of the number of Kupffer cells, natural killer (NK) cells and NK T cells. The expression of endothelial adhesion molecules is higher in the liver than in other organs[15], which demonstrates that the inflammatory response, oxidative stress, and immune response may play important roles in COVID-19-related liver injury. Moreover, SARS-CoV-2-induced cytotoxicity, ischemia, drug toxicity, and triggering of pre-existing liver diseases are also possible contributors to the pathogenesis of COVID-19-related liver injury[16,17]. However, the exact mechanism of COVID-19-related liver injury remains unclear.

Nuclear factor erythroid 2-related factor 2 (NRF2) is a nuclear transcription factor that is activated by oxidative stress and belongs to the family of Cap’n’Collar family of basic leucine zippers[18,19]. Kelch-like ECH-associated protein-1 (KEAP1), a redox-regulated substrate adaptor protein, which interacts with the Cul3-dependent ubiquitin ligase complex[20]. The antioxidant response element (ARE), an electrophilic
response element, is a cis-regulatory element[21]. NRF2 is recognized as a regulator of oxidative stress, and KEAP1-NRF2-ARE is one of the most important pathways of antioxidant and anti-inflammatory element signaling[22]. Under homeostasis, NRF2 binds to KEAP1 and is anchored to the cytoplasm[23]. When cells are attacked by ROS or other stimuli, NRF2 dissociates from KEAP1 and is quickly translocated to the nucleus, forming a heterodimer with the transcriptional regulator and binding to an ARE[24]. The complex ultimately activates the expression of antioxidant enzymes and thus leads to the removal of excessive ROS in the body, thereby exerting antioxidant effects[25]. Then, NRF2 is degraded in the nucleus through the β-transducin repeat-containing protein-glycogen synthase kinase 3 (β-TrCP-GSK3) axis or by translocating to the cytoplasm and becoming rapidly degraded by KEAP1[26]. Since the outbreak of COVID-19, continuous studies have shown that enhancing immunity, establishing resistance to the inflammatory response, and reducing oxidative stress are keys to COVID-19 treatment, while NRF2 may be an important target for COVID-19 treatment and plays a protective role because of its dual anti-viral and anti-inflammatory properties [27]. Currently, NRF2 activators, such as 4-octyl-itaconate (4-OI) and dimethyl fumarate (DMF), can be used for the treatment of COVID-19[28]. As most liver injury is associated with increased oxidative stress and an overloaded antioxidant defense system, NRF2 may also be an ideal therapeutic target for treating chronic liver disease. Indeed, NRF2 has previously been shown to protect liver cells in viral hepatitis[29,30], drug-induced liver injury[31-33], cholestasis liver injury[34-36], fatty liver[37,38], and other liver diseases by reversing insulin resistance, inhibiting gluconeogenesis and lipid accumulation, and enhancing the anti-inflammatory and antioxidative effects[39]. We speculate that NRF2 may also play a regulatory role in COVID-19-related liver injury. In this review, we systematically describe the reciprocal regulation between NRF2 and inflammatory mediators in COVID-19-related liver injury.

**NRF2 AND INFLAMMATORY MEDIATORS**

Cytokines are small-molecule messengers secreted by cells, and they can exert effects on the same type of cell in the organ periphery and cells in other organs[40]. Most cytokines are in a lytic state, and some exist in membrane form. Cytokines can be secreted by most cells and possess a wide range of functions. Interleukins (ILs) are a group of cytokines that were first seen to be expressed by white blood cells. Chemically attractive cytokines are called chemokines. Cytokines that interfere with viral replication are called interferons (IFNs).

When the body is stimulated by endogenous or exogenous stimuli such as viruses, it usually triggers the immune defense system and oxidative stress response to maintain homeostasis. This process is often accompanied by the production of many cytokines [41], which interfere with mitochondrial function and lead to the production of a large amount of ROS, thereby inducing the expression of IL-1, IL-6, tumor necrosis factor alpha (TNF-α), IL-8 receptor-β (CXCR2), monocyte chemotactic protein-1, and cell adhesion molecule 1 and promoting the aggregation of macrophages and chemotactic neutrophils[42-44]. Then neutrophils produce myeloperoxidase and catalyze the production of large amounts of hypochlorous acid, which kills cells through strong oxidation reactions[45]. Cell injury induces the expression of high mobility group box 1, osteopontin, and Toll-like receptor 4, recruiting more neutrophils, amplifying the inflammatory response, and further aggravating tissue injury[46].

It is thought that COVID-19 patients suffer from cytokine storm symptoms and an uncontrolled release of proinflammatory cytokines. The levels of proinflammatory factors such as IL-1β, IL-2, IL-8, IL-9, IL-10, TNF-α, and other inflammatory factors are higher in COVID-19 patients than in healthy adults[47,48]. Serum inflammatory cytokine levels are positively correlated with indicators of liver dysfunction in patients, suggesting potential mechanisms between liver injury and the inflammatory response[49]. NRF2 negatively regulates the expression of these inflammatory cytokines. For example, in human macrophages, NRF2 can inhibit the expression of inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, by blocking the recruitment of RNA polymerase II, thus reducing the inflammatory response. Moreover, an agonist of NRF2 represses the replication of SARS-CoV-2 and the inflammatory response[50].

The NRF2-activating compound resveratrol is a growth suppressor and apoptosis promoter in liver cancer cells[51]. Resveratrol can reduce the expression of IL-1β. Another NRF2-activating compound, PB125, which contains the active ingredients carnosol, withaferin A, and luteolin, significantly downregulates IL-1β, IL6, TNF-α,
intercellular adhesion molecule 1, vascular cell adhesion molecule 1 (VCAM1), E-selectin, and IFN-γ-induced gene expression[52]. The inflammatory response and oxidative stress are the main pathological features of COVID-19, and disease progression has been related to redox imbalance. The NRF2 antioxidant pathway is suppressed in COVID-19 patients and cells infected with SARS-CoV-2. The NRF2 agonists 4-Oi and DMF can inhibit the replication of SARS-CoV-2[28]. All of these findings support the idea that NRF2 has dual antiviral and anti-inflammatory properties and may be a potential therapeutic target for the treatment of COVID-19.

Pre-existing liver disease may play an important role in COVID-19-related liver injury, since an investigation found that a small proportion of patients with COVID-19 also have pre-existing liver diseases[54-56]. This effect may be due to the significant decrease in the number of lymphocytes, CD4+ T cells, CD8+ T cells, B cells, and NK cells in patients with COVID-19, which prevents a proper immune response[57], ultimately leading to the recurrence of pre-existing liver disease. Glucocorticoids effectively reduce mortality in patients with severe COVID-19[58]. In addition to its anti-inflammatory function, glucocorticoids also have immunosuppressive effects, which can also participate in the reactivation of pre-existing diseases.

As shown in Figure 1, inflammatory molecules are involved in the interactions with NRF2 in viral infection, as listed in a dataset generated by Ingenuity pathway analysis (IPA). They include IL1A, IL1B, IL4, IL5, IL6, IL10, IL13, IL19, IL36G, IL1RN, IFNGR2, IFNG, IFI19, CXCR3, CCL2, CCL11, CXCL1, CXCL5, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL20, CXCL21, IFNAR1, TNF, and TNFβ. Current literature shows that these molecules are related to the COVID-19-mediated inflammatory response[41-48].

INTERPLAY OF NRF2/NF-κB AND INFLAMMATORY MEDIATORS IN COVID-19-RELATED LIVER INJURY

Activated nuclear factor kappa-B (NF-κB) is a key transcription factor in the inflammatory response and oxidative stress. The NF-κB signal transduction pathway is a typical proinflammatory pathway[59]. There are five members in the NF-κB family: p50 (NF-κB1), p52 (NF-κB2), p65 (RelA), RelB, and c-Rel[60]. Under physiological conditions, NF-κB and inhibitor kappa B (IκB) combine and are maintained in the cytoplasm in an inactive state. Upon viral infection or other stimuli, IκB is phosphorylated under the action of IκB kinase (IKK) and is then ubiquitinated by the β-TrCP-Skp1-Cullin1 pathway, resulting in the release and nuclear translocation of NF-κB, inducing the production of a large number of inflammatory mediators, and leading to oxidative stress and inflammatory cascades, thereby affecting cell survival, mutation, and proliferation[61]. According to current studies, NRF2 plays a beneficial role mainly by regulating redox metabolism through interactions with NF-κB and regulating proinflammatory genes[62-64]. Several studies have shown reciprocal regulation between NRF2 and NF-κB in inflammatory diseases[65]. Moreover, the activation of NF-κB can promote the release of different types of cytokines, such as IL-1, IL-2, IL-6, IL-12, TNF-α and granulocyte-macrophage colony stimulating factor, which can directly participate in acute and chronic inflammation of the liver[66]. Activated nuclear factor kappa-B (NF-κB) and oxidative stress are the main pathological features of COVID-19, and disease progression has been related to redox imbalance. The NRF2 antioxidant pathway is suppressed in COVID-19 patients and cells infected with SARS-CoV-2. The NRF2 agonists 4-Oi and DMF can inhibit the replication of SARS-CoV-2[28]. All of these findings support the idea that NRF2 has dual antiviral and anti-inflammatory properties and may be a potential therapeutic target for the treatment of COVID-19.

Interplay of NRF2/NF-κB and inflammatory mediators in COVID-19-related liver injury

According to current studies, NRF2 plays a beneficial role mainly by regulating redox metabolism through interactions with NF-κB and regulating proinflammatory genes[62-64]. Several studies have shown reciprocal regulation between NRF2 and NF-κB in inflammatory diseases[65]. Moreover, the activation of NF-κB can promote the release of different types of cytokines, such as IL-1, IL-2, IL-6, IL-12, TNF-α and granulocyte-macrophage colony stimulating factor, which can directly participate in acute and chronic inflammation of the liver (Figure 2), causing liver injury[60]. Among these cytokines, TNF-α is a cytokine mainly produced by macrophages/monocytes and is involved in the gene expression of growth factors, cytokines, transcription factors, and receptors[66]. There are two types of TNF-α receptors: TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). TNF-α can activate NF-κB through the TNFR1-NF-κB signaling axis[66], and in turn, NF-κB promotes the expression of inflammatory cytokines[60], thereby forming a negative cycle that further feeds the destructive cytokine storm and aggravates damage to the liver tissue[36,67,68]. According to previous studies, lipopolysaccharides can promote NF-κB- and NRF2-mediated responses[69]. The initial proinflammatory response is driven by NF-κB[60], and when the activity of NRF2 reaches its maximum level, NF-κB activation is inhibited. NF-κB subunits p50 and p65 can induce NRF2 transcription by binding specific sites of NRF2, and NRF2 can inhibit the expression of NF-κB in turn upon IκB dephosphorylation[62]. CBP-p300, a transcriptional auxiliary activator, can acetylate nonhistone proteins, such as NRF2 and p65, the lysine residues of which are equipped with acetyl groups, enhancing gene transcription[70-72]. NRF2 has 605 amino acid residues and six conserved domains, namely, Neh4-Neh6[18,19]. CBP can bind to Neh4 and Neh5 of NRF2, resulting in acetylation of the Neh1 domain. In addition, CBP can bind to phosphorylated p65 at Ser276. Overexpressed p65 can
Figure 1 An interaction network analysis (Ingenuity pathway analysis) was performed to predict nuclear factor, erythroid 2-like 2-mediated inflammatory cytokine-related genes in viral infections. Solid lines indicate direct regulation, and dotted lines depict indirect interactions. ABCC2: ATP-binding cassette subfamily C member 2; ACE: Angiotensin I-converting enzyme; ACE2: Angiotensin I-converting enzyme 2; C5: Complement C5; Ccl2: Chemokine (C-C motif) ligand 2; CCL: C-C motif chemokine ligand; CXCR3: C-X-C motif chemokine receptor 3; CYSLTR1: Cysteinyl leukotriene receptor 1; F10: Coagulation factor X; IFNB1: Interferon beta 1; IFNG: Interferon gamma; IFNGR2: Interferon gamma receptor 2; IL: Interleukin; IL1A: Interleukin 1 alpha; IL1B: Interleukin 1 beta; IL1RN: Interleukin 1 receptor antagonist; IL36G: Interleukin 36 gamma; MST1R: Macrophage-stimulating 1 receptor; NF2: Nuclear factor, erythroid 2-like 2; PF4: Platelet factor 4; PIP5K1C: Phosphatidylinositol-4-phosphate 5-kinase type 1 gamma; SPP1: Secreted phosphoprotein 1; TGF-beta: Transforming growth factor beta; TNF: Tumor necrosis factor; TNFRSF1A: TNF receptor superfamily member 1A; VCAM1: Vascular cell adhesion molecule 1.

KEAP1 competitively bind to CBP, thereby inhibiting the transcriptional activity of NRF2 but enhancing the transcriptional activity of NF-kB promoter genes[70]. KEAP1 is the intermediate link between NRF2 and NF-kB. ARE is a cis-acting element, and the NRF2-ARE pathway is the most important endogenous antioxidant excitation pathway[73]. On one hand, p65 can increase the nuclear level of KEAP1 to inhibit the NRF2-ARE pathway, thus reducing the expression of cytoprotective enzymes. On the other hand, KEAP1 can initiate the autophagic degradation of inhibitor of NF-kB kinase subunit β (IKKβ) by preventing the binding of heat shock protein 90 (HSP90) to IKKβ. Additionally, KEAP1 can specifically bind to IKKβ and then connect with the ubiquitin connexin CUL3-RBX1 complex, which promotes IKKβ degradation and inhibits the expression of NF-kB[74].

COVID-19 is always accompanied by an increase in inflammatory cells and proinflammatory factors. Oxidative stress is an important mechanism for the occurrence and development of COVID-19, and is closely related to the prognosis of the disease[12]. ROS are the key agents in oxidative stress; some researchers propose monitoring ROS levels as diagnostic criteria for COVID-19[75]. As a key regulator of oxidative stress and inflammation, NF-kB plays an important role in the progression of COVID-19. In patients with COVID-19, a severe systemic inflammatory response is always followed by acute respiratory distress syndrome (ARDS) and sepsis, which leads to tissue ischemia and hypoxia and the generation of ROS, thus activating the NF-kB pathway[76]. In addition, Hirano et al[77] proposed that ACE2 is the key factor in the early stage of COVID-19, and the IL-6-signal transducer and activator of transcription 3 (STAT3) axis plays an important role in the inflammatory cytokine storm in the late stage of the disease. ACE2 is necessary for SARS-CoV-2 entry, and it can also inactivate angiotensin 2 (AngII), which can play a proinflammatory role via the angiotensin 2 receptor (AT1R). SARS-CoV, has high homology with SARS-CoV-2 and binds to ACE2 on the cell membrane, which results in an increase in AngII in serum[78]. In animal models, AT1R inhibitors can prevent ARDS caused by SARS-CoV infection[78]. The AngII-AT1R axis also activates NF-kB and ADAM metallopeptidase domain 17 (ADAM17), which can promote the production of an epidermal growth
Figure 2 An ingenuity pathway analysis was performed to predict nuclear factor, erythroid 2-like 2/nuclear factor kappa B-mediated inflammatory cytokine-related genes in viral infections. Solid lines indicate direct regulation, and dotted lines depict indirect interactions. ACE: Angiotensin I-converting enzyme; Ccl2: Chemokine (C-C motif) ligand 2; CXCL: C-X-C motif ligand; IL: Interleukin; IL1B: Interleukin 1 beta; IFNG: Interferon gamma; IL1RN: Interleukin 1 receptor antagonist; NFKB1: Nuclear factor kappa B subunit 1 (p50); RELA: RELA proto-oncogene, NF-κB subunit (p65); TNF: Tumor necrosis factor; TNFRSF1A: TNF receptor superfamily member 1A; VCAM1: Vascular cell adhesion molecule 1.
Table 1 Characteristics of liver injury during coronavirus disease

| Ref.        | Total number of patients | Proportion of liver injury, (%) | Proportions of pre-existing liver diseases, n (%) | Others                                                                 |
|------------|--------------------------|--------------------------------|-----------------------------------------------|----------------------------------------------------------------------|
| Guan et al[87] | 1099                     | Elevated AST 168/757 (22.2); Elevated ALT 158/741 (21.3); Elevated TB 76/722 (10.5) | 23 (2.1)                                                                 | Liver injury was the most common complication among these patients |
| Lian et al[56] | 465                      | 61 (13.1)                      | 19 (4.1)                                      | Liver damage is an independent prognostic factor of COVID-19          |
| Chen et al[89] | 503                      | 301 (69.8)                     | NA                                           |                                                                      |
| Jin et al[55]  | 651                      | 64 (9.8)                       | 25 (3.8)                                      |                                                                      |
| Xie et al[69]  | 79                       | Elevated ALT (31.6); Elevated AST (35.4); Elevated TB (5.1) | NA                                           | COVID-19 with liver injury in non-ICU hospitalized patients was common |
| Wang et al[90] | 293                      | 19 (6.5)                       | 12 (4.1)                                      | Compared with the survival group, the non-survival group was more prone to complications of acute liver injury |
| Chen et al[91] | 274                      | Elevated AST 84 (31)           | 11 (4)                                        | The frequency of liver injury in the deceased patients was significantly higher than that in the recovered patients |
| Yu et al[54]   | 1633                     | Elevated AST 298/1445 (20.6); Elevated AST 303/1445 (21.0) | 38 (2.3)                                      | Severe patients are more likely to have liver injury than mild patients |

ALT: Alanine transaminase; AST: Aspartate aminotransferase; ICU: Intensive care unit; NA: Not applicable; TB: Total bilirubin.

(GS or GSr1), GSH reductase (GR), GSH peroxidase (GPx), and GSH S-transferases (GSTs) [92]. The tricarboxylic acid cycle (TCA cycle) is the central link and cross hub of glucose metabolism, lipid metabolism, and protein metabolism. NRF2 participates in the TCA cycle by regulating the expression of glucose 6-phosphate dehydrogenase (G6PD), malic enzyme 1, and isocitrate dehydrogenase (IDH), which are involved in the production of NADPH, a key cofactor in promoting antioxidant reactions [93-95]. NRF2 can also affect intermediate metabolism, increases the availability of substrates for the mitochondrial respiratory chain, and increases nicotinamide adenine dinucleotide phosphate (NADPH) production through crosstalk between the glycolysis and pentose phosphate pathways [96]. In addition, under oxidative stress or starvation, NRF2 helps maintain mitochondrial homeostasis, clears oxidized or damaged proteins and organelles and removes excessive ROS, providing a favorable environment for cell survival [97]. In conclusion, NRF2 can play roles in antioxidative stress and cell protection by maintaining redox homeostasis in the body.

Many researchers have proposed the hypothesis that COVID-19-related liver damage may be caused by systemic inflammatory response to viral infection. After SARS-CoV-2 infection and the increased production of ROS [98], the inflammation response of the body is activated and the expression of proinflammatory cytokines including IL-1β, IL-6, IL-8, and TNF-α is greatly increased, and immune cells are continuously activated and are accumulating [99,100]. The combined effects of many immune cells and proinflammatory factors lead to a cytokine storm [4,99-102], which may further result in multiple organ function damage, including liver dysfunction, and even the death of the patient [103,104]. Moreover, there seems to be a positive correlation between the severity of COVID-19 and the level of inflammation [57,100, 105-107], and the incidence of liver damage is related to the severity of COVID-19 [13], which also reveals the close relationship between COVID-19-related liver injury and the inflammatory response. Since many cases of limb [108], gastrointestinal [109], heart [110], and cerebral [111] ischemia have been reported, it is reasonable to suspect that tissue ischemia is among the causes of COVID-19-related liver injury, in which the inflammatory response may cause local blood stasis, vascular endothelial destruction and excessive activation of the coagulation system, leading to local thrombosis and tissue ischemia, ultimately resulting in liver injury. Moreover, severe inflammatory reactions, such as sepsis [76], which cause hemodynamic instability and lead to ischemia, may also be among the causes of liver injury. Strong evidence points to the major causes for liver injury involve the systemic inflammatory response and...
oxidative stress following SARS-CoV-2 infection.

Regarding the mechanisms of direct damage and inflammation-induced damage after SARS-CoV-2 infection, heme oxygenase 1 (HO-1) seems to be involved and could represent a therapeutic strategy. HO-1 can inhibit the replication of influenza A virus, human respiratory syncytial virus, and hepatitis B virus, among others. In all cases, viral replication blockade is achieved through the type I IFN response mediated by HO-1[112]. Therefore, it is reasonable to assume that HO-1 inhibits SARS-CoV-2 replication by the same mechanism. HO-1 and its metabolites have significant anti-inflammatory effects via NRF2. HO-1 metabolizes free heme into carbon monoxide (CO), biliverdin and iron, exhibiting cell protection and anti-apoptosis and immune regulation properties[113]. In animal models of sepsis and renal ischemia-reperfusion injury with significant systemic inflammatory responses, HO-1 showed great anti-inflammatory effects and its overexpression provided cell protection[112]. Hence, it can be speculated that HO-1 counteracts the cytokine storm produced by COVID-19. Additionally, the CO product of HO-1 can stimulate the release of hydrogen sulfide (H$_2$S)[114]. H$_2$S is a natural defense against enveloped RNA virus infections that can activate regulatory T cells, maintain the body’s immune homeostasis, and exert antiviral effects[114]. H$_2$S can also oversulfate the KATP channel on the white blood cell membrane to keep it open, preventing white blood cells adherence to the endothelium and triggering the inflammatory cascade[114]. On the one hand, H$_2$S regulates endothelial cell function and attenuates ischemia. On the other hand, H$_2$S controls the body’s inflammatory response and prevents liver injury. Therefore, HO-1 activated by NRF2 can inhibit viral replication to control viral infection and can also balance host defenses through the HO-1/CO/H$_2$S axis, protecting endothelial structures, improving ischemia, and protecting the liver from damage induced by SARS-CoV-2 infection.

Figure 3 shows reciprocal regulation between NRF2/redox-related genes and inflammatory mediators. In particular, upregulation of NRF2/HO-1 (HMOX1) may be an important strategy for the treatment of the liver damage caused by COVID-19.

**NRF2-MYC IS A KEY TARGET FOR INFLAMMATORY MEDIATORS IN COVID-19-RELATED LIVER INJURY**

NRF2 consists of seven highly conserved domains, NRF2-ECH homology 1 (Neh1) to Neh7. Each of the Neh domains executes distinct functions[18,19]. Neh1 is a CNC-bZIP domain that allows NRF2 to heterodimerize with small musculoaponeurotic fibrosarcoma (MAF) proteins (MAFF, MAFG, and MAFK)[115]. Under normal physiological conditions, NRF2 is degraded via the ubiquitin-proteasome pathway in a KEAP1-dependent manner and maintained at a basal level[36]. Under stress conditions, the cysteine residues in KEAP1 are modified when they are oxidized, causing the loss of its adaptor activity[20]. Then NRF2 is disengaged from the regulatory complex, is phosphorylated, and accumulates in the nucleus, where it heterodimerizes with small MAF proteins and regulates ARE-driven genes[115]. These proteins regulate transcription when they dimerize among themselves[116,117]; that is, they seem to serve as transcriptional activators by dimerizing with other basic zipper proteins such as NFE2L2[115]. The interaction of MAFF and NFE2L2 results in activation of the ARE, which is present at the promoter-proximal region of many genes involved in the antioxidant defense and triggers the expression of certain genes[115]. MAFF expression is induced by oxidative stressors, such as hydrogen peroxide and electrophilic compounds, increasing NRF2 and GSH expression and activating the NRF2-ARE pathway[118]. NRF2 exerts protective effects on various liver diseases [119,120]. Therefore, NRF2 can also be a therapeutic target and NRF2 activators can also be used for the treatment of COVID-19-related liver injury. MAFF, as a molecular chaperone is required for the function of NRF2, may also be a target for the treatment of COVID-19-related liver injury.

C-MYC is a family of proto-oncogenes and encodes a nuclear phosphoprotein that plays roles in cell cycle progression, apoptosis, and cell transformation[121]. MNT is a MAX network transcriptional repressor[122]. C-MYC and MNT each have a basic helix-loop-helix-zipper domain (bHLHzip) with which they bind the canonical DNA sequence CACGTG, known as an E-box, following heterodimerization with MAX proteins. The protein complexes bind to the E-box DNA sequence and regulate the transcription of specific target genes[122]. The MYC-MAX and MNT-MAX networks comprise transcription factors that regulate gene-specific transcription[122]. The heterodimer MNT-MAX is a transcriptional repressor, and the heterodimer MYC-MAX is a transcriptional activator[123-125]. We also reported that c-MYC can interact
Figure 3 An ingenuity pathway analysis was performed to predict NRF2/redox-related genes and inflammatory cytokine-related gene expression in viral infections. Solid lines indicate direct regulation, and dotted lines depict indirect interactions. Ccl2: Chemokine (C-C motif) ligand 2; CXCL: C-X-C motif ligand; GCLC: Glutamate-cysteine ligase catalytic subunit; GCLM: Glutamate-cysteine ligase modifier subunit; GPX1: Glutathione peroxidase 1; HMOX1: Heme oxygenase 1 (HO-1); IFN: Interferon; IL: Interleukin; TNF: Tumor necrosis factor; TNFRSF1A: TNF receptor superfamily member 1A; VCAM1: Vascular cell adhesion molecule 1.

with NRF2 to repress NRF2-mediated transactivation of the ARE[126]. Their interaction may regulate the oxidative stress pathway. An IPA showed the interactions among NFE2L2/MAF/MYC/MNT and inflammatory mediators. NRF2/MYC/MNT/MAFG are involved with inflammatory mediators IL10, IL1A, IL1B, IL36G, IL4, IL5, IL6, IFNG, IFNG, CXCL8, VCAM1, TNF, TGF-β, SPP1 and MST1R (Figure 4).

Upon analyses of a protein-protein interaction network with 65 intersecting targets, c-MYC was found to be one of the core targets for COVID-19 treatment[127]. MAFG and c-MYC are upregulated and MNT is downregulated in liver injury[125,128]. MAX directly interacts with the c-MYC, MAFG, MNT, and NRF2 proteins, whereas c-MYC and MAFG interact with NRF2. As shown in Figure 5, these complexes bind to the E-box region in the promoters of the c-MYC and MAFG genes, leading to gene activation. The complexes can also bind to AREs, leading to the dysregulation of the following genes: TXN-related genes (TXN, TXNrd1, and Srxn1); ROS and xenobiotic detoxification-related genes (GSTA1/2 and GSTM1/2/3), GSTP1, and Nqo1; heme and ion metabolism-related genes (HMOX1 or HO-1, Fth1, and Fth); NADPH regeneration-related genes (G6pD, PgD, IDH1 and Me1); and GSH production-related genes (XCT, GCLC, GCLM, and GSRI). This gene dysregulation may lead to COVID-19-related cytokine storm and liver injury.

SEVERITY OF LIVER INJURY IN TERMS OF ADVERSE OUTCOMES OF SARS-COV-2 INFECTION

Alanine aminotransferase (ALT) was selected to represent liver injury rather than aspartate aminotransferase (AST) because the sources of extrahepatic AST are very common, including the heart and skeletal muscle during related muscle breakdown. Therefore, in patients infected with SAR-CoV-2, we classified liver damage into normal/mild (< 2 fold the upper limit of normal, upper limit of normal [ULN]), moderate (2- to 5-fold ULN), and severe (> 5 fold ULN) according to the degree of ALT elevation (Table 2)[129].

Normal and mild liver injury account for the largest proportion (60%-90%) of SAR-CoV-2-infected patients. Severe liver injury accounts for less than 20% of these patients. In addition, moderate to severe liver injury is more common in patients requiring intensive care unit (ICU) care. However, in general, the most common liver injury is mild liver injury, and the degree of liver injury is independently related to the occurrence of end events (ICU admission, death, mechanical injury)[129-131]. Only 5% of COVID-19 patients acquire severe liver damage[132]. The Cai et al[133] study
Table 2: Classification of the severity of liver injury in terms of the adverse outcome of coronavirus disease

| Ref.          | Date                          | Cohort | Normal/mild (< 2 times ULN) | moderate (2-5 times ULN) | Severe (> 5 times ULN) | How the ULN was defined                      |
|---------------|-------------------------------|--------|-----------------------------|--------------------------|------------------------|---------------------------------------------|
| Phipps et al  | March 8, 2020-April 14, 2020  | 2273   | 1784 (78.5)                 | 344 (15.1)               | 145 (6.4)              | ALT = 50 U/L                                |
| Mendizabal et al | April 15, 2020-July 31, 2020 | 1611   | 322 (84.7)                  | 185 (11.5)               | 61 (3.8)               | ALT (the reference value of different institutions) |
| Hundt et al   | March 14, 2020-April, 2020    | 1753   | 1123 (64.1)                 | 408 (23.3)               | 222 (12.7)             | ALT = 34 U / L                              |
| Yip et al     | January 23, 2020-May 1, 2020  | 816    | 635 (77.8)                  | 141 (17.3)               | 40 (4.9)               | ALT = 40 U / L                              |

Data are expressed as n (%). ALT: Alanine aminotransferase; ULN: Upper limit of normal.

Figure 4: An ingenuity pathway analysis was performed to predict that nuclear factor, erythroid 2-like 2/MYC proto-oncogene, bHLH transcription factor/MAX network transcriptional repressor/MAF bZIP transcription factor G regulates the corresponding inflammatory cytokines. Solid lines indicate direct regulation, and dotted lines depict indirect interactions. CXCL: C-X-C motif ligand; MAFG: MAF bZIP transcription factor G; MAX: MYC-associated factor X; MNT: MAX network transcriptional repressor; MYC: MYC proto-oncogene, bHLH transcription factor; IFN: Interferon; IL: Interleukin; TGF-beta: Transforming growth factor beta; TNF: Tumor necrosis factor; TNFRSF1A: TNF receptor superfamily member 1A; VCAM1: Vascular cell adhesion molecule 1.

showed that the incidence of liver injury in hospitals was higher than that at the time of admission. For these patients, few other factors affected liver test abnormalities, such as potential liver disease or drug use. Therefore, it can be speculated that the occurrence of liver damage is caused by COVID-19. Zhao et al[134] compared patients with mild COVID-19 systems with non-infected patients. The absolute value of lymphocyte level differences in the two groups was low, and there was no difference in C-reactive protein or IL-6 level. ALT was not elevated in patients with pneumonia unrelated to COVID-19 when they were admitted to the hospital, but it was elevated in 28% of COVID-19 patients. Compared with the general inflammation caused by other pathogens, the specific inflammation caused by COVID-19 is more likely to cause abnormal liver function. Additionally, severe liver damage caused by SARS-CoV-2 infection is associated with serum inflammatory markers (white blood cell count and neutrophil-to-lymphocyte ratio are significantly higher). Age, hypertension, and the presence of diabetes are negatively correlated with severe liver damage in COVID-19 patients[129]. It can be speculated that young patients may have a stronger immune and inflammatory response to infection, which may lead to more severe liver damage. In other words, the inflammatory response can cause liver damage and determine the degree of liver damage. Therefore, inflammation plays an important role in the development of liver injury induced by COVID-19. Because of the individual response to the virus, different patients may exhibit different degrees of liver injury; therefore, it is necessary to grade the degree of liver injury. We described the anti-inflammatory
CONCLUSION

There are many reasons for COVID-19-related liver injury including the inflammatory response and oxidative stress, ischemia, drug toxicity, SARS-CoV-2 cytotoxicity, and pre-existing liver disease. Regardless of the etiology, inflammatory cell infiltration, cell necrosis, and liver tissue fibrosis may be the final pathological result. As an important transcription factor of antioxidant stress and anti-inflammation, NRF2 can exert protective effects on COVID-19-related liver injury. The KEAP1-NRF2-ARE, NRF2-HO-1, NRF2-MYC/MNT/MAFG, and NRF2-NF-κB pathways are potential preventive and therapeutic targets in COVID-19-related liver injury.

ACKNOWLEDGEMENTS

We thank the authors of the primary studies for their responses to our information requests.

REFERENCES

1. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol 2020; 10: 587269 [PMID: 33324574 DOI: 10.3389/fcimb.2020.587269]

2. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The Architecture of SARS-CoV-2 Transcriptome. Cell 2020; 181: 914-921. e10 [PMID: 32330414 DOI: 10.1016/j.cell.2020.04.011]

3. Mrityunjaya M, Pavithra V, Neelam R, Janhavi P, Halmani PM, Ravindra PV. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. Front Immunol 2020; 11: 570122 [PMID: 33117359 DOI: 10.3389/fimmu.2020.570122]

4. Cuadrado A, Pajares M, Benito C, Jiménez-Villegas J, Escoll M, Fernández-Ginés R, García Yague
Properties in the Management of Viral Pneumonia.

Lin CY

10.1128/MCB.01204-10

independent manner.

glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-

Phytother Res

via

Gastroenterol

Tang W

[PMID: 32477830] DOI: 10.1016/j.jhep.2020.05.002

Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39: 529-539 [PMID: 28466096 DOI: 10.1007/s00281-017-0629-x]

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433 [PMID: 32113704 DOI: 10.1016/j.jaut.2020.102433]

Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 2020; 73: 807-816 [PMID: 32437830 DOI: 10.1016/j.jhep.2020.05.002]

Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. Pharmacotherapy 2020; 40: 843-856 [PMID: 32542785 DOI: 10.1002/phar.2438]

Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol 2020; 26: 2233-2332 [PMID: 32476796 DOI: 10.3748/wjg.v26.i19.2232]

Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; 5: 428-430 [PMID: 32145190 DOI: 10.1016/S2468-2535(20)30057-1]

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420-422 [PMID: 32085846 DOI: 10.1016/S2213-2600(20)30076-X]

Wang Q, Zhao H, Liu LG, Wang YB, Zhang T, Li MH, Xu YL, Gao GJ, Fan Y, Cao Y, Ding R, Wang JJ, Cheng C, Xie W. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil Med Res 2020; 7: 28 [PMID: 32507110 DOI: 10.1186/s40779-020-00256-6]

Jothimani D, Venugopal R, Abedin MF, Kaliamparithy I, Rela M. COVID-19 and the liver. J Hepatol 2020; 73: 1231-1240 [PMID: 32553666 DOI: 10.1016/j.jhep.2020.06.006]

Caraballo C, Jaimis F. Organ Dysfunction in Sepsis: An Ominous Trajectory From Infection To Death. Yale J Biol Med 2019; 92: 629-640 [PMID: 31866778]

Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int 2020; 40: 1278-1281 [PMID: 32251539 DOI: 10.1111/liv.14470]

Karakike E, Giannarollos-Bourboulis EJ. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front Immunol 2019; 10: 55 [PMID: 30766533 DOI: 10.3389/fimmu.2019.00055]

Tonelli C, Chio IIC, Tuveson DA. Transcriptional Regulation by Nrf2. Antioxid Redox Signal 2018; 29: 1727-1745 [PMID: 28891999 DOI: 10.1089/ars.2017.7342]

Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 2014; 39: 199-218 [PMID: 24647116 DOI: 10.1016/j.tibs.2014.02.002]

Kopacek A, Kloska D, Forman HJ, Grochot-Przeczek A. Beyond repression of Nrf2: An update on Keap1. Free Radic Biol Med 2020; 157: 63-74 [PMID: 32234331 DOI: 10.1016/j.freeradbiomed.2020.03.023]

Lu MC, Ji JA, Jiang ZY, You QD. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev 2016; 36: 924-963 [PMID: 27192495 DOI: 10.1002/med.21396]

Sajadimajd S, Khazaei M. Oxidative Stress and Cancer: The Role of Nrf2. Curr Cancer Drug Targets 2018; 18: 538-557 [PMID: 28969555 DOI: 10.2174/1568009617666171002144228]

David JA, Rifkin WJ, Rabbani PS, Ceradini DJ. The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus. J Diabetes Res 2017; 2017: 4826724 [PMID: 28913364 DOI: 10.1155/2017/4826724]

Tang W, Jiang YF, Ponnusamy M, Diaiolo M. Role of Nrf2 in chronic liver disease. World J Gastroenterol 2014; 20: 13079-13087 [PMID: 25278702 DOI: 10.3748/wjg.v20.i36.13079]

Cui Y, Xin H, Tao Y, Mei L, Wang Z. Atenolol diminishes attenuates pulmonary fibrosis in mice via the activation of Nrf2 pathway and the inhibition of NF-κB/TGF-beta1/Smad2/3 pathway. Phytother Res 2021; 35: 974-986 [PMID: 32996197 DOI: 10.1002/ptr.6857]

Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 2011; 31: 1121-1133 [PMID: 21245377 DOI: 10.1128/MCB.01204-10]

Lin CY, Yao CA. Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia. Infect Drug Resist 2020; 13: 1735-1741 [PMID: 32606823 DOI: 10.2147/IDR.S256773]
Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With COVID-19

Wu C, Li M, Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46: 846-848 [PMID: 32125452 DOI: 10.1007/s00134-020-05991-x]

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With COVID-19

Zhu DD et al. NRF2 in COVID-19-related liver injury

28 Olganer D, Farahani E, Thyrsted J, Blay-Cadanet J, Herengt A, Idorn M, Hain A, Hernaiz B, Knudsen A, Iversen MB, Schilling M, Jorgensen SE, Thomsen M, Reinhart LS, Lappe M, Hoang HD, Gilchrist VH, Hansen AL, Ottosson R, Nielsen CG, Moller C, van der Horst D, Peri S, Balachandran S, Huang J, Jakobsen M, Uvegniens EB, Poulsen TB, Bartsch L, Tielke AL, Luo Y, Alain T, Rehwinkel J, Alcami A, Hiscott J, Mogensen TH, Paludan SR, Holm CK. SARS-CoV-2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun 2020; 11: 4938 [PMID: 33094001 DOI: 10.1038/s41467-020-18764-1]

29 Espinoza JA, González PA, Kalergs AM. Modulation of Antiviral Immunity by Heme Oxygenase-1. Am J Pathol 2017; 187: 487-493 [PMID: 28982120 DOI: 10.1016/j.ajpath.2016.11.011]

30 Ruan Y, Jiang Y, Wang W, Ma J, He B, Chen M. HBV down-regulates PTEN expression via Nrf2/GSK3β signaling pathway. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2020; 45: 1099-1014 [PMID: 33051413 DOI: 10.10187/j.issn.1672-7347.2020.200189]

31 Goldring CE, Kitteringham NR, Elsby R, Randle LE, Clement VN, Williams DP, McMahon M, Hayes JD, Itoh K, Yamamoto M, Park BK. Activation of hepatic NRF2 in vivo by acetaminophen in CD-1 mice. Hepatology 2004; 39: 1267-1276 [PMID: 15127755 DOI: 10.1002/hep.20183]

32 Jadeja RN, Urrunaga NH, Dash S, Khurana S, Saxena NK. Withaferin-A Reduces Acetaminophen-Induced Liver Injury in Mice. Biochem Pharmacol 2015; 97: 122-132 [PMID: 26212553 DOI: 10.1016/j.bcp.2015.07.024]

33 Liu J, Wu KC, Lu YF, Ekuase E, Klasseen CD. Nrf2 protection against liver injury produced by various hepatotoxins. Oxid Med Cell Longev 2013; 2013: 305861 [PMID: 23766851 DOI: 10.1155/2013/305861]

34 Tan KP, Wood GA, Yang M, Ito S. Participation of nuclear factor (erythroid 2-related), factor 2 in ameliorating lithocholic acid-induced cholestatic liver injury in mice. Br J Pharmacol 2010; 161: 1111-1121 [PMID: 20977460 DOI: 10.1111/j.1476-5381.2010.00953.x]

35 Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Sugimoto H, Utsunomiya H, Oda K, Warabi E, Ishii T, Yamamoto M. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Biochem Biophys Res Commun 2009; 389: 431-436 [PMID: 19732748 DOI: 10.1016/j.bbrc.2009.08.156]

36 Alesksunes LM, Slitt AL, Maher JM, Dieter MZ, Knight TR, Goedken M, Cherrington NJ, Chan JY, Klasseen CD, Manautou JE. Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)/H:quinone oxidoreductase 1 during cholestasis. Cell Stress Chaperones 2006; 11: 356-363 [PMID: 17228845 DOI: 10.1379/csc.217.1]

37 Sugimoto H, Okada K, Shoda J, Wang W, Ishige K, Ueda T, Taguchi K, Yangawa T, Nakahara A, Hyodo I, Ishii T, Yamamoto M. Deletion of nuclear factor-E2-related factor-2 Leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2010; 298: G283-G294 [PMID: 19926817 DOI: 10.1152/ajpgi.00296.2009]

38 Lamlé J, Marhenke S, Borlak J, von Wasielewski R, Eriksson CJ, Geffers R, Manns MP, Yamanoto M, Vogel A. Nuclear factor-erythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 2008; 134: 1159-1168 [PMID: 18395094 DOI: 10.1053/j.gastro.2008.01.011]

39 Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kensing TW, Dinkova-Kostova AT. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov 2019; 18: 295-317 [PMID: 30610225 DOI: 10.1038/s41573-018-0008-x]

40 Oppenheim JJ. Cytokines: past, present, and future. Int J Hematol 2001; 74: 3-8 [PMID: 11530802 DOI: 10.1007/bf02982543]

41 Dinarello CA. Historical insights into cytokines. Eur J Immunol 2007; 37 Suppl 1: S34-S45 [PMID: 17972543 DOI: 10.1002/eji.2007737772]

42 Konishi T, Schuster RM, Goetzman HS, Caldwell CC, Lentsch AB. Cell-specific regulatory effects of CXC42 on cholestatic liver injury. Am J Physiol Gastrointest Liver Physiol 2019; 317: G773-G783 [PMID: 31604030 DOI: 10.1152/ajpgi.00080.2019]

43 Saito JM, Maher JJ. Bile duct ligation in rats induces biliary expression of cytokine-induced neutrophil chemoattractant. Gastroenterology 2000; 118: 1157-1168 [PMID: 10833491 DOI: 10.1016/s0016-5085(00)70369-6]

44 Jones H, Alpini G, Francis H. Bile acid signaling and biliary functions. Acta Pharm Sin B 2015; 5: 123-128 [PMID: 26579437 DOI: 10.1016/j.apsb.2015.01.009]

45 Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects Med 2017; 56: 45-53 [PMID: 28606651 DOI: 10.1016/j.mam.2017.06.001]

46 Wenzel P, Kossmann S, Müntzel T, Daiber A. Redox regulation of cardiovascular inflammation - Immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species. Free Radic Biol Med 2017; 109: 48-60 [PMID: 28108270 DOI: 10.1016/j.freeradbiomed.2017.01.027]

47 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46: 846-848 [PMID: 32125452 DOI: 10.1007/s00134-020-05991-x]

48 Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Wu KC, Lu YF, Ekuase E, Klaassen CD. NRF2 protection against liver injury produced by various hepatotoxins. Oxid Med Cell Longev 2013; 2013: 305861 [PMID: 23766851 DOI: 10.1155/2013/305861]
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. JAMA Intern Med 2020; 180: 934-943

[PMID: 32167524 DOI: 10.1001/jamaopthalmology.2020.0994]

Yang RX, Zheng RD, Fan JG. Etiology and management of liver injury in patients with COVID-19. World J Gastroenterol 2020; 26: 4753-4762. [PMID: 32921955 DOI: 10.3748/wjg.v26.i32.4753]

Robledinos-Antón N, Fernández-Ginés R, Manda G, Cuadrado A. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev 2019; 2019: 9372182. [PMID: 31396308 DOI: 10.1155/2019/9372182]

Yang H, Zheng Y, Li TW, Peng H, Fernández-Ramos D, Martínez-Chantar ML, Rojas AL, Mato JM, Lu SC. Methionine adenosyltransferase 2B, HUr, and sirtuin 1 protein cross-talk impacts on the effect of resveratrol on apoptosis and growth in liver cancer cells. J Biol Chem 2013; 288: 23161-23170. [PMID: 23814050 DOI: 10.1074/jbc.M113.487157]

McCord JM, Hybertson BM, Cota-Gomez A, Geraci KP, Gao B. Nrf2 Activator PB125® as a Potential Therapeutic Agent against COVID-19. Antioxidants (Basel) 2020; 9. [PMID: 32545518 DOI: 10.3390/antiox9060518]

Rana AK, Rahmatkar SN, Kumar A, Singh D. Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Cytokine Growth Factor Rev 2021; 58: 92-101. [PMID: 32948440 DOI: 10.1016/j.cytogfr.2020.08.002]

Yu C, Lei Q, Li W, Wang X, Liu W. Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience. J Infect Public Health 2020; 13: 1202-1209. [PMID: 32718894 DOI: 10.1016/j.jiph.2020.07.002]

Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, Hao SR, Jia HY, Cai H, Zhang XL, Yu GD, Xu KJ, Wang XY, Gu QJ, Zhang SY, Ye CY, Jin CL, Lu YF, Xu Y, Yu XP, Huang JX, Xu KL, Qi Q, Yu CB, Zhu B, Li YT, Liu J, Zhao H, Zhang X, Yu L, Guo YZ, Su JW, Tao J, Lang GJ, Wu XX, Wu WR, Qv TT, Xiang DR, Yi P, Shi D, Chen Y, Ren Y, Qiu YQ, Li LJ, Sheng J, Yang Y. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020; 69: 1002-1009. [PMID: 32213556 DOI: 10.1136/gutjnl-2020-320926]

Lian J, Jin X, Hao S, Jia H, Cai H, Zhang X, Hu J, Zheng L, Wang X, Zhang S, Ye C, Jin C, Yu G, Gu J, Lu Y, Yu X, Xiang D, Li L, Liang T, Sheng J, Yang Y. Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. Influenza Other Respir Viruses 2020; 14: 564-574. [PMID: 32397011 DOI: 10.1111/irv.12758]

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Fang J, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506. [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detty M, Estcourt L, Fitzgerald M, Gooßen H, Green C, Hanflit R, Higgins AM, Horvát C, Huerta SJ, Kruger P, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, Marshall J, McAuley M, McGlothlin A, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Rowan K, Sani A, Santos M, Saunders C, Seymur C, Turner A, van de Veerdonk F, Vennkatesh B, Zarychanski R, Berry S, Lewis RJ, McArthur C, Webb SA, Gordon AC. Writing Committee for the REMAP-CAP Investigators, Angus DC, de Jonge M, Gordon A, Lawler P, Webb S, Campbell L, Forbes A, Gattas D, Hertier S, Higgins L, Peake S, Presneill J, Seppelt I, Trapani T, Young P, Bagshaw S, Daneman N, Ferguson N, Misak C, Huerta SJ, Pletz M, Rohde G, Alexander B, Basile K, Girard T, Huang D, Vates J, Beasley R, Fowler R, McCollough S, Morpeth S, Paterson D, Uyeki T, Baille J, Duff J, Hills T, Orr K, Patanawala A, Tong S, Netea M, Bihari S, Carrier M, Ferguson G, Goligher E, Haidar G, Hunt B, Kumar A, Pletz M, Rohde G, Alexander B, Basile K, Girard T, Huang D, Vates J, Beasley R, Fowler R, McCollough S, Morpeth S, Paterson D, Uyeki T, Baille J, Duff J, Hills T, Orr K, Patanawala A, Tong S, Netea M, Bihari S, Carrier M, Ferguson G, Goligher E, Haidar G, Hunt B, Kumar A, Laffan M, Lawless P, Lother S, McCallum P, Middeldorp S, McQuilten Z, Neal M, Pasi J, Tong S, Netea M, Bihari S, Carrier M, Ferguson G, Goligher E, Haidar G, Hunt B, Kumar A, Laffan M, Lawless P, Lother S, McCallum P, Middeldorp S, McQuilten Z, Neal M, Pasi J, Schutgens R, Stanworth S, Surgeon A, Weissman A, Adhikari N, Anstey M, Brant E, de Man A, Lamonagne F, Massa MH, Udy A, Arnold D, Begin P, Charlewood R, Chasse M, Coyne M, Cooper J, Daly J, Gosbell I, Harvalla-Simmonds H, MacLennan S, Menon D, McDyer J, Pridee N, Roberts S, Shankar-Hari M, Thomas H, Timmough A, Triulzi D, Walsh T, Wood E, Calfee C, O’Kane C, Shyamsundar M, Sinha P, Thompson T, Young I, Hodgson C, Lafaye J, Orford N, Neto A, Lewis R, McGlothlin A, Miller E, Singh V, Zammit C, van Bentum Puijk W, Bouwman W, Mangindaan Y, Parker L, Peters S, Rietveld I, Raymakers G, Kuant R, Brillingen N, Markgraf R, Arrinsough K, Brickell A, Anjum A, Lane JB, Richards-Belle A, Saull M, Wiley D, Bion J, Connor J, Gates S, Manax V, van der Poll T, Reynolds J, van Beurden M, Effelant C, Schotsman J, Boyd C, Harland C, Shearer A, Wren J, Clermont G, Garrard K, King A, Ricketts D, Malakoutis S, Marroquin O, Music E, Quinn K, Roquetti M, Pearson K, Collins J, Collins H, Jackson P, Jackson S, Asghar A, Dyas S, Sutu M, Murphy S, Williamson D, Mguni N, Potter A, Porter D, Goodwin J, Rook C, Harrison S, Williams H, Campbell H, Lomme K, Williamson J, Sheffield J, van’t Hoff W, McCracken P, Young M, Board J, Mart E, Knott C, Smith J, Boschert C, Affleck J, Ramanan M, D’Souza R, Pateman K, Shahik A, Cheung W, Kol M, Wong H, Shah A, Wagh A, Simson P, Duke G, Chan P, Cartner B, Hunter S, Laver R, Shrestha T, Regli A, Pellicano A, McCullough J, Tallott M, Kumar N, Panwar R, Brinkerhoff G, Koppen C, Cazzola F, Brain M, Minaelli S, Fischer R, Biradar V, Soar N, White H, Estensen K, Morrison L, Cooper M, Health M, Shehaby Y, Al-Bassam W, Hulley A, Whitehead C, Lowrey J, Gresha R, Walsham J, Meyer J, Harward M, Venz E,
Zhu DD et al. NRF2 in COVID-19-related liver injury
Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405. Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage.

Sellers K, Bradley-Potts J, Yates D, Birkinshaw I, Kell K, Marshall N, Carr-Knott L, Summers C. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020; 324: 1317-1329 [PMID: 32876697 DOI: 10.1001/jama.2020.17022]

Zhu DD et al. NRF2 in COVID-19-related liver injury

Cherian S, Cutler S, Roynon-Reed A, Harrington K, Raithatha A, Bauchmuller K, Ahmad N, Grecu I, Trodd D, Martin J, Wrey Brown C, Arias AM, Craven T, Hope D, Singleton J, Clark S, Rae N, Welters I, Hamilton DO, Williams K, Waugh V, Shaw D, Puthucheary Z, Martin T, Santos F, Uddin R, Somerville A, Tatham KC, Jhanji S, Black E, Dela Rosa A, Howie R, Tully R, Drummond A, Dearden J, Philbin J, Munt S, Vuylsteke A, Chan C, Victor S, Matsa R, Gellmannucho M, Creagh-Brown B, Tooley J, Montague L, De Beaux F, Bullman L, Kersiade I, Demreticio C, Mitchell S, Ramos L, White K, Dominson P, Johns M, Casey R, Mattocks L, Salisbury S, Dark P, Claxton A, McLachlan D, Slevin K, Lee S, Hulme J, Joseph S, Kinney F, Senya HJ, Oborska A, Kayani A, Hadebe B, Orath Prabakaran R, Nichols L, Worner R, Faulkner B, Gendall E, Hayes K, Hamilton-Davies C, Mfuko C, Abbass H, Mandadapu V, Leaver S, Forton D, Patel K, Paramasivam E, Powell M, Gould R, Wilby E, Howcroft C, Banach D, Fernández de Pinedo Artaraz Z, Caberros L, White I, Croft M, Holland N, Pereira R, Zakia A, Johnson D, Jackson M, Garrard H, Juhasz V, Roy A, Rostron A, Woods L, Cornell S, Pillar S, Harford R, Rees T, Ivtat H, Sundara Raman A, Davey M, Lee K, Barber R, Chablanli M, Brohi F, Jagannathan V, Clark M, Purvis S, Wetherill B, Dushianthan A, Cusack R, de Courcy-Golder K, Smith S, Attwood B, Parsons P, Page V, Zhao XB, Oza D, Rhodes J, Anderson T, Morris S, Xia Le Tai C, Thomas A, Keen A, Digby S, Cowley N, Southern D, Reddy H, Campbell A, Watkins C, Smuts S, Touna O, Barnes N, Alexander P, Featon T, Ferguson S, Sellers K, Bradley-Potts J, Yates D, Birkinshaw I, Kell K, Marshall N, Carr-Knott L, Summers C. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020; 324: 1317-1329 [PMID: 32876697 DOI: 10.1001/jama.2020.17022]

Yu M, Li H, Liu Q, Liu F, Tang L, Li C, Yuan Y, Zhan Y, Xu W, Li W, Chen H, Ge C, Wang J, Yang X. Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway. Cell Signal 2011; 23: 883-892 [PMID: 21262351 DOI: 10.1016/j.cellsig.2011.01.014]

Probst BL, McCauley L, Trevino I, Wigley WC, Ferguson DA. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405. PLoS One 2015; 10: e0135257 [PMID: 26301306 DOI: 10.1371/journal.pone.0135257]
Zhu DD et al. NRF2 in COVID-19-related liver injury

75 Miripour ZS, Sarrami-Forooshani R, Sanati H, Makarem J, Taheri MS, Shojaeian F, Eskafi AH, Abbassvandi F, Namdar N, Ghafari H, Aghaei P, Zandi A, Faramarzpour M, Hoseinazadi M, Tayebi M, Abdolahad M. Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic. *Biosens Bioelectron* 2020; 165: 112435 [PMID: 32729548 DOI: 10.1016/j.bios.2020.112435]

76 Cecchini R, Cecchini AL. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. *Med Hypotheses* 2020; 143: 110102 [PMID: 32721799 DOI: 10.1016/j.mehy.2020.110102]

77 Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. *Immunity* 2020; 52: 731-733 [PMID: 32325025 DOI: 10.1016/j.immuni.2020.04.003]

78 Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, DENG W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensins converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005; 11: 875-879 [PMID: 16007097 DOI: 10.1038/nm1267]

79 Eguchi S, Kawai T, Scala R, Rizzo V. Understanding Angiostatin II Type 1 Receptor Signaling in Vascular Pathophysiology. *Hypertension* 2018; 71: 804-810 [PMID: 29581215 DOI: 10.1161/HYPERTENSIONAHA.118.110266]

80 Murakami M, Kaminura D, Hirano T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. *Immunity* 2019; 50: 812-831 [PMID: 30995501 DOI: 10.1016/j.immuni.2019.03.027]

81 Cichóz-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. *World J Gastroenterol* 2014; 20: 8082-8091 [PMID: 25093860 DOI: 10.3748/wjg.v20.i25.8082]

82 Yu HH, Qiu YX, Li B, Peng CY, Zeng R, Wang W. Kadsura heteroclitica stem ethanol extract protects against carbon tetrachloride-induced liver injury in mice via suppression of oxidative stress, inflammation, and apoptosis. *J Ethnopharmacol* 2021; 267: 113496 [PMID: 33091494 DOI: 10.1016/j.jep.2021.113496]

83 Wakabayashi N, Shin S, Slocum SL, Agoston ES, Wakabayashi J, Kwak MK, Misra V, Biswal S, Yamamoto M, Kessler TW. Regulation of notch1 signaling by nrf2: implications for tissue regeneration. *Sci Signal* 2010; 3: ra52 [PMID: 20628156 DOI: 10.1126/scisignal.2000762]

84 Duarte TL, Caldis C, Santos AG, Silva-Gomes S, Santos-Gonçalves A, Martins MJ, Porto G, Lopes JM. Genetic disruption of NRF2 promotes the development of necroinflammation and liver fibrosis in a mouse model of HFE-hereditary hemochromatosis. *Redox Biol* 2017; 11: 157-169 [PMID: 27926457 DOI: 10.1016/j.redox.2016.11.013]

85 Wu KC, Liu JJ, Klaassen CD. Nrf2 activation prevents cadmium-induced acute liver injury. *Toxicol Appl Pharmacol* 2012; 263: 14-20 [PMID: 22677785 DOI: 10.1016/j.taap.2012.05.017]

86 Luedde T, Schwabe RF. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2011; 8: 108-118 [PMID: 21293511 DOI: 10.1038/nrgastro.2010.213]

87 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CI, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YY, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; 382: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

88 Chen LY, Chu HK, Bai T, Tu SJ, Wei Y, Li ZL, Hu LL, Zhu R, Zhang L, Han CQ, Xiao L, He Q, Song J, Liu WH, Zhu QJ, Chen H, Yang L, Hou XH. Liver damage at admission is an independent prognostic factor for COVID-19. *J Dig Dis* 2020; 21: 512-518 [PMID: 32713118 DOI: 10.1111/1751-2986.12925]

89 Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver Int* 2020; 40: 1321-1326 [PMID: 32239591 DOI: 10.1111/liv.14449]

90 Wang Z, Ye D, Wang M, Zhao M, Li D, Ye J, Liu J, Xu Y, Zhang J, Pan W, Liu M, Luo Z, Wan J. Clinical Features of COVID-19 Patients with Different Outcomes in Wuhan: A Retrospective Observational Study. *Biomed Res Int* 2020; 2020: 2138387 [PMID: 33029494 DOI: 10.1155/2020/2138387]

91 Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; 395: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

92 Lu SC. Regulation of glutathione synthesis. *Mol Aspects Med* 2009; 30: 42-59 [PMID: 18601945 DOI: 10.1016/j.mam.2008.05.005]

93 Thimmulappa RK, Mai KH, Srisuma S, Kessler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. *Cancer Res* 2002; 62: 5196-5203 [PMID: 12334904]

94 Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Abaratani H, Yamamoto M, Motohashi H. Nrf2 directs glucose and glutamine into anabolic pathways in metabolic reprogramming. *Cancer Cell* 2012; 22: 66-79 [PMID: 22789539 DOI: 10.1016/j.ccr.2012.05.016]
95 Wu KC, Cui JY, Klaassen CD. Beneficial role of Nrf2 in regulating NAPDH generation and consumption. Toxicol Sci 2011; 123: 590-600 [PMID: 21775727 DOI: 10.1093/toxsci/kfr183]

96 Holmström KM, Kostov RV, Dinkova-Kostova AT. The multifaceted role of Nrf2 in mitochondrial function. Curr Opin Toxicol 2016; 6: 80-91 [PMID: 28066829 DOI: 10.1016/j.cotox.2016.10.002]

97 Hu Q, Ren J, Li G, Wu J, Wu X, Wang G, Gu G, Ren H, Hong Z, Li J. The mitochondrially targeted antioxidant MitoQ protects the intestinal barrier by ameliorating mitochondrial DNA damage via the Nrf2/ARE signaling pathway. Cell Death Dis 2018; 9: 403 [PMID: 29540694 DOI: 10.1038/cddis.2018.9]

98 Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, Prodonoff JS, Carregari VC, de Biaggi Junior CAO, Cruñff F, Jimenez Restrepo JL, Vendramini PH, Reis-de-Oliveira G, Bispo Dos Santos K, Toledo-Teixeira DA, Parise PL, Martinic MC, Marques RE, Carmo HR, Borin A, Coimbra LD, Boldrini VO, Brunetti NS, Vieira AS, Mansour E, Ulauf RG, Bernardes AF, Nunes TA, Ribeiro LC, Palma AC, Agrela MV, Moretti ML, Sposito AC, Pereira FB, Veloso LA, Vinolo MAR, Damasio A, Proença-Módena JL, Carvalho RF, Mori MA, Martins-de-Souza D, Nakaya H, Farias AS, Moraes-Vieira PM. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell Metab 2020; 32: 437-446. e5 [PMID: 32697943 DOI: 10.1016/j.cmet.2020.07.007]

99 Martínez-Sánchez G, Schwartz A, Donná PVV. Potential Cytoprotective Activity of Oxzone Therapy in SARS-CoV-2/COVID-19. Antioxidants (Basel) 2020; 9 [PMID: 32384798 DOI: 10.3390/antiox9050389]

100 Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019 (COVID-19). The Perspectives of clinical immunologists from China. Clin Immunol 2020; 12 [PMID: 32471251 DOI: 10.3390/jnu12061562]

101 Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014; 24: R453-R462 [PMID: 24845678 DOI: 10.1016/j.cub.2014.03.034]

102 Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin 2020; 35: 266-271 [PMID: 32125642 DOI: 10.1007/s12250-020-00207-4]

103 Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38: 1-9 [PMID: 32105090 DOI: 10.12932/AP200220-0772]

104 Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71: 762-768 [PMID: 32161940 DOI: 10.1093/cid/ciaa249]

105 Niki H, Nakaya HI, Farias AS, Moraes-Vieira PM. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell Metab 2020; 32: 437-446. e5 [PMID: 32697943 DOI: 10.1016/j.cmet.2020.07.007]

106 Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, Prodonoff JS, Carregari VC, de Biaggi Junior CAO, Cruñff F, Jimenez Restrepo JL, Vendramini PH, Reis-de-Oliveira G, Bispo Dos Santos K, Toledo-Teixeira DA, Parise PL, Martinic MC, Marques RE, Carmo HR, Borin A, Coimbra LD, Boldrini VO, Brunetti NS, Vieira AS, Mansour E, Ulauf RG, Bernardes AF, Nunes TA, Ribeiro LC, Palma AC, Agrela MV, Moretti ML, Sposito AC, Pereira FB, Veloso LA, Vinolo MAR, Damasio A, Proença-Módena JL, Carvalho RF, Mori MA, Martins-de-Souza D, Nakaya H, Farias AS, Moraes-Vieira PM. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell Metab 2020; 32: 437-446. e5 [PMID: 32697943 DOI: 10.1016/j.cmet.2020.07.007]

107 Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014; 24: R453-R462 [PMID: 24845678 DOI: 10.1016/j.cub.2014.03.034]

108 Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin 2020; 35: 266-271 [PMID: 32125642 DOI: 10.1007/s12250-020-00207-4]

109 Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38: 1-9 [PMID: 32105090 DOI: 10.12932/AP200220-0772]

110 Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71: 762-768 [PMID: 32161940 DOI: 10.1093/cid/ciaa249]

111 Niki H, Nakaya HI, Farias AS, Moraes-Vieira PM. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell Metab 2020; 32: 437-446. e5 [PMID: 32697943 DOI: 10.1016/j.cmet.2020.07.007]

112 Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10: 102-108 [PMID: 32282863 DOI: 10.1016/j.jpha.2020.03.001]

113 Bellosta R, Luzzani L, Natalini G, Pegorier MA, Attisani L, Cossu LG, Ferrandina C, Fossati A, Conti E, Bush RL, Piagnerelli M, Van Meerhaeghe A, Zouaoui Boudjeltia K, Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome. Med Hypotheses 2020; 144: 110242 [PMID: 33254548 DOI: 10.1016/j.mehy.2020.110242]

114 Calay D, Mason JC. The multifunctional role and therapeutic potential of HO-1 in the vascular endothelium. Antioxid Redox Signal 2014; 20: 1789-1809 [PMID: 24131232 DOI: 10.1089/ars.2013.5659]

115 Battilo M. The role of host defences in Covid 19 and treatments thereof. Mol Med 2020; 26: 90 [PMID: 32993497 DOI: 10.1186/s10020-020-00216-9]

116 Raghunath A, Sundarraj K, Nagarajan R, Arfuso F, Biao J, Kumar AP, Sethi G, Perumal E. Antioxidant response elements: Discovery, classes, regulation and potential applications. Redox Biol 2018; 17: 297-314 [PMID: 29775961 DOI: 10.1016/j.redox.2018.05.002]

117 Motohashi H, Katsuka F, Miyoshi C, Uchiuma Y, Saitoh H, Francastel C, Engel JD, Yamamoto K. Antioxidant response elements: Discovery, classes, regulation and potential applications. Redox Biol 2018; 17: 297-314 [PMID: 29775961 DOI: 10.1016/j.redox.2018.05.002]
Infect Dis the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia With Other Pneumonias. Zhao D, Liu L, Xu L. COVID-19: Abnormal liver function tests. Cai Q. Gut. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Yip TC. A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. patients with COVID-19 and abnormal liver tests on admission. Bessone F, Rubinstein F, Silva MO. Prospective Latin American cohort evaluating outcomes of Barradas M, Contreras F, Scarpin A, Schinoni MI, Toledo C, Girala M, Mainardi V, Sanchez A, Venturelli MG, Varón A, Vera-Pozo E, Tagle M, García M, Tassara A, Brutti J, Ruiz García S, Toro LG, Díaz J, Gonzalez Ballerga E, Miranda-Zazueta G, Peralta M, Gutiérrez I, Michelato D, Mendizabal M. Verna EC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in Phipps MM. Zhou ZG, Mato JM, Seki E, Liu T, Yang H, Lu SC. Reciprocal Regulation Between Forkhead Box Li Y. Activation of a novel c-Myc-miR27-prohibitin 1 circuitry in cholestatic liver injury inhibits cholangiocarcinoma growth in mice and humans(‡). Hepatology 2016; 64: 439-455 [PMID: 26969892 DOI: 10.1002/hep.28541]

Yang H. Li TW, Zhou Y, Peng H, Liu T, Zandi E, Martinez-Chantar ML, Mato JM, Lu SC. Activation of a novel c-Myc-miR27-prohibitin 1 circuitry in cholestatic liver injury inhibits glutathione synthesis in mice. Antioxid Redox Signal 2015; 22: 259-274 [PMID: 25226451 DOI: 10.1089/ars.2014.6027]

Zeng Y, Lou G, Ren Y, Li T, Zhang X, Wang J, Huang Q. Network pharmacology-based analysis of Zukunma granules for the treatment of COVID-19. Eur J Integr Med 2021; 42: 101282 [PMID: 33425074 DOI: 10.1016/j.eujim.2020.101282]

Li Y, Lu L, Tu J, Zhang J, Xiong T, Fan W, Wang J, Li M, Chen Y, Steggerda J, Peng H, Li TW, Zhou ZG, Mato JM, Seki E, Liu T, Yang H, Lu SC. Reciprocal Regulation Between Forkhead Box M1/ NF-κB and Methionine Adenosyltransferase 1A Drives Liver Cancer. Hepatology 2020; 2020; 6182-17090 [PMID: 32080887 DOI: 10.1002/hep.31196]

Philipps MM, Barraza LH, LaSota ED, Sobieszczky ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verme VC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology 2020; 72: 807-817 [PMID: 32473607 DOI: 10.1002/hep.31404]

Mendizábal M, Piñero F, Ridruajo E, Anders M, Silveyra MD, Torres A, Montes P, Urzúa A, Pages M, Toro LG, Díaz J, Gonzalez Ballerga E, Miranda-Zazueta G, Peralta M, Gutiérrez I, Michelato D, Venturelli MG, Varón A, Vera-Pozo E, Tagle M, García M, Tassara A, Bruttì R, Ruiz García S, Bustios C, Escadañillo N, Macias Y, Higuera-de-la Tijera F, Gómez AJ, Domínguez A, Castillo-Barradas M, Contreras F, Scarpin A, Schinoni MI, Toledo C, Girala M, Mainardi V, Sanchez A, Bessoné F, Rubinstein F, Silva MO. Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission. Ann Hepatol 2021; 21: 100298 [PMID: 33359234 DOI: 10.1016/j.ajhep.2020.100298]

Hundt MA, Deng Y, Ciareleglio MM, Nathanhon MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology 2020; 72: 1169-1176 [PMID: 32725890 DOI: 10.1002/hep.31487]

Yip TC, Lui GC, Wong VW, Chow VC, Ho TH, Li TC, Tse YK, Hui DS, Chan HL, Wong GL. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut 2021; 70: 733-742 [PMID: 32641471 DOI: 10.1136/gutjnl-2020-321726]

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. J Hepatol 2020; 73: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]

Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, Guo F, Zhao H, Gao R. A Comparative Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia With Other Pneumonias. Clin Infect Dis 2020; 71: 756-761 [PMID: 32161968 DOI: 10.1093/cid/ciaa247]
